Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

INCB-099318

Alternative Names: incb-099318, incb099318, incb 099318, INCB99318, INCB-99318, INCB 99318
Latest Update: 2025-01-26
Latest Update Note: Clinical Trial Update

Product Description

Incyte is developing incb-099318, an Oral agent for advanced solid tumors

Mechanisms of Action: PD-L1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Mesothelioma|Ovarian Cancer|Penile Cancer|Esophageal Cancer|Small Cell Lung Cancer|Clear Cell Sarcoma|Nasopharyngeal Cancer|Transitional Cell Carcinoma|Basal Cell Carcinoma|Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Renal Cell Carcinoma|Colorectal Cancer|Small Cell Sarcoma|Cervical Cancer|Endometrial Cancer|Carcinoma, Merkel Cell|Oncology Solid Tumor Unspecified|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
INCB 99318-122

P1

Terminated

Ovarian Cancer|Cervical Cancer|Small Cell Lung Cancer|Penile Cancer|Colorectal Cancer|Carcinoma, Merkel Cell|Endometrial Cancer|Nasopharyngeal Cancer|Squamous Cell Carcinoma|Clear Cell Sarcoma|Transitional Cell Carcinoma|Basal Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Esophageal Cancer|Renal Cell Carcinoma|Mesothelioma|Small Cell Sarcoma

2024-08-16

ACTRN12620000118909

P1

Completed

Healthy Volunteers|Oncology Solid Tumor Unspecified

2021-07-27

Recent News Events

Date

Type

Title

04/30/2024

News Article

 Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs

10/31/2023

News Article

 Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

08/01/2023

News Article

 Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

05/02/2023

News Article

 Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions